MANAGEMENT OF ARTAVA DUSHTI W.S.R TO POLYCYSTIC OVARIAN SYNDROME WITH AROGYAVARDHINI RASA AND PATHADI CHOORNA.
- Conditions
- Health Condition 1: E282- Polycystic ovarian syndrome
- Registration Number
- CTRI/2021/02/030954
- Lead Sponsor
- IPGT AND RA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Both married /unmarried patients in the age group of 18-40yrs.
Patients with any 3 or more clinical features of PCOS like-
Amenorrhea or Oligomenorrhoea
Anovulation
Infertility (Due to anovulation)
Acne
Hirsutism (Ferriman-Gallwey scale)
Obesity (BMI above 25)
Acanthosis nigricans
Along with confirmation of any one Polycystic Ovary in USG finding.
1.Patients suffering from Pelvic/Systemic diseases like (Endometriosis, Hydrosalpinx, Fibroid uterus,).
2.Organic lesions of reproductive tract like T.B, Carcinoma and Congenital deformities.
3.Patients with history of Cardiac diseases, Chronic liver disease.
4.Age group <18yrs and > 40yrs will be excluded.
5.Uncontrolled Hypertension (Systolic BP above 150 & Diastolic above100mmhg), Uncontrol led Diabetes mellitus (above the range of 160-200 mg/dl, FBS)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It is expected that trial drug help to improve anovulation ,oligoovulation ,hirsutism ,amenorrhea ,acne ,infertility, obesityTimepoint: 4 weeks after completion of clinical trial.
- Secondary Outcome Measures
Name Time Method Drug may have effect on ovulation induction and conception.Timepoint: After the followup period.